{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:32:47Z","timestamp":1791574367938,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To investigate the prognostic factors of extraocular muscle restriction in patients with thyroid eye disease (TED), 65 patients with TED and restrictive myopathy were evaluated. Demographics, clinical activity score (CAS), smoking status, thyroid disease status, thyroid hormone status, thyroid autoantibody status, orbital computed tomography (CT) scan at initial presentation, and treatment regimens were assessed. The movements of the most severely affected extraocular muscles were categorized into five grades. The patients were divided into the improved and the not-improved group based on the improvement in the limitation of the extraocular muscle excursion (LOM) throughout the follow-up, and the groups were compared using clinical factors. The mean LOM significantly improved from 2.3\u2009\u00b1\u20091.1 to 1.7\u2009\u00b1\u20091.2 after 1\u00a0year of follow-up. The excursion of the most restricted muscle improved in 32 patients but not in 33 patients during the follow-up. The initial concentration of the thyroid-stimulating antibody (TSAb) was significantly lower in the improved (229.3\u2009\u00b1\u2009114.1) than in the not-improved group (345.0\u2009\u00b1\u2009178.6) (<jats:italic>P<\/jats:italic>\u2009=\u20090.02) Age, sex, smoking status, CAS, thyroid status, and muscle thickness on the CT scan did not significantly differ in the groups. This study showed that the initial concentration of TSAb is a factor affecting the recovery of restrictive myopathy.<\/jats:p>","DOI":"10.1038\/s41598-021-93275-9","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T10:21:22Z","timestamp":1625221282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic factors of restrictive myopathy in thyroid eye disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Jae Hwan","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Duck","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung In","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"93275_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/WNO.0000000000000132","volume":"34","author":"SJ Shan","year":"2014","unstructured":"Shan, S. J. & Douglas, R. S. The pathophysiology of thyroid eye disease. J. Neuroophthalmol. 34, 177\u2013185. https:\/\/doi.org\/10.1097\/WNO.0000000000000132 (2014).","journal-title":"J. Neuroophthalmol."},{"key":"93275_CR2","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/s0002-9440(10)63488-8","volume":"163","author":"L Koumas","year":"2003","unstructured":"Koumas, L., Smith, T. J., Feldon, S., Blumberg, N. & Phipps, R. P. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am. J. Pathol. 163, 1291\u20131300. https:\/\/doi.org\/10.1016\/s0002-9440(10)63488-8 (2003).","journal-title":"Am. J. Pathol."},{"key":"93275_CR3","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1210\/jc.2011-2890","volume":"97","author":"S Kumar","year":"2012","unstructured":"Kumar, S., Iyer, S., Bauer, H., Coenen, M. & Bahn, R. S. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves\u2019 orbital fibroblasts: Inhibition by an IGF-I receptor blocking antibody. J. Clin. Endocrinol. Metab. 97, 1681\u20131687. https:\/\/doi.org\/10.1210\/jc.2011-2890 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"93275_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1210\/jcem.85.2.6333","volume":"85","author":"JP Aniszewski","year":"2000","unstructured":"Aniszewski, J. P., Valyasevi, R. W. & Bahn, R. S. Relationship between disease duration and predominant orbital T cell subset in Graves\u2019 ophthalmopathy. J. Clin. Endocrinol. Metab. 85, 776\u2013780. https:\/\/doi.org\/10.1210\/jcem.85.2.6333 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"93275_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000237532","volume":"113","author":"S Romagnani","year":"1997","unstructured":"Romagnani, S. et al. An update on human Th1 and Th2 cells. Int. Arch. Allergy Immunol. 113, 153\u2013156. https:\/\/doi.org\/10.1159\/000237532 (1997).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"93275_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/wno.0000000000000128","volume":"34","author":"MT Bhatti","year":"2014","unstructured":"Bhatti, M. T. & Dutton, J. J. Thyroid eye disease: Therapy in the active phase. J. Neuroophthalmol. 34, 186\u2013197. https:\/\/doi.org\/10.1097\/wno.0000000000000128 (2014).","journal-title":"J. Neuroophthalmol."},{"key":"93275_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena, L. et al. The 2016 European Thyroid Association\/European group on graves\u2019 orbitopathy guidelines for the management of graves\u2019 orbitopathy. Eur. Thyroid J. 5, 9\u201326. https:\/\/doi.org\/10.1159\/000443828 (2016).","journal-title":"Eur. Thyroid J."},{"key":"93275_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1210\/er.2002-0020","volume":"24","author":"BS Prabhakar","year":"2003","unstructured":"Prabhakar, B. S., Bahn, R. S. & Smith, T. J. Current perspective on the pathogenesis of graves\u2019 disease and ophthalmopathy. Endocr. Rev. 24, 802\u2013835. https:\/\/doi.org\/10.1210\/er.2002-0020 (2003).","journal-title":"Endocr. Rev."},{"key":"93275_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nri1412","volume":"4","author":"TA Wynn","year":"2004","unstructured":"Wynn, T. A. Fibrotic disease and the T(H)1\/T(H)2 paradigm. Nat. Rev. Immunol. 4, 583\u2013594. https:\/\/doi.org\/10.1038\/nri1412 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"93275_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2169\/internalmedicine.53.1518","volume":"53","author":"Y Hiromatsu","year":"2014","unstructured":"Hiromatsu, Y., Eguchi, H., Tani, J., Kasaoka, M. & Teshima, Y. Graves\u2019 ophthalmopathy: Epidemiology and natural history. Internal Med. (Tokyo, Jpn.) 53, 353\u2013360 (2014).","journal-title":"Internal Med. (Tokyo, Jpn.)"},{"key":"93275_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/jc.2012-3119","volume":"98","author":"KA Ponto","year":"2013","unstructured":"Ponto, K. A. et al. Public health relevance of Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 98, 145\u2013152. https:\/\/doi.org\/10.1210\/jc.2012-3119 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"93275_CR12","first-page":"73","volume":"4","author":"WR Nunery","year":"1991","unstructured":"Nunery, W. R. Ophthalmic Graves\u2019 disease: A dual theory of pathogenesis. Ophthalmol. Clin. N. Am. 4, 73\u201387 (1991).","journal-title":"Ophthalmol. Clin. N. Am."},{"key":"93275_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00002341-199709000-00001","volume":"13","author":"WR Nunery","year":"1997","unstructured":"Nunery, W. R., Nunery, C. W., Martin, R. T., Truong, T. V. & Osborn, D. R. The risk of diplopia following orbital floor and medial wall decompression in subtypes of ophthalmic Graves\u2019 disease. Ophthalm. Plast Reconstr. Surg. 13, 153\u2013160. https:\/\/doi.org\/10.1097\/00002341-199709000-00001 (1997).","journal-title":"Ophthalm. Plast Reconstr. Surg."},{"key":"93275_CR14","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/nejm199311113292007","volume":"329","author":"RS Bahn","year":"1993","unstructured":"Bahn, R. S. & Heufelder, A. E. Pathogenesis of Graves\u2019 Ophthalmopathy. N. Engl. J. Med. 329, 1468\u20131475. https:\/\/doi.org\/10.1056\/nejm199311113292007 (1993).","journal-title":"N. Engl. J. Med."},{"key":"93275_CR15","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1210\/jc.2005-2813","volume":"91","author":"AK Eckstein","year":"2006","unstructured":"Eckstein, A. K. et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease. J. Clin. Endocrinol. Metab. 91, 3464\u20133470. https:\/\/doi.org\/10.1210\/jc.2005-2813 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"93275_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn, R. S. Graves\u2019 ophthalmopathy. N. Engl. J. Med. 362, 726\u2013738. https:\/\/doi.org\/10.1056\/NEJMra0905750 (2010).","journal-title":"N. Engl. J. Med."},{"key":"93275_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1089\/thy.2006.16.967","volume":"16","author":"B Gopinath","year":"2006","unstructured":"Gopinath, B. et al. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves\u2019 disease with and without ophthalmopathy: Correlation with clinical features. Thyroid 16, 967\u2013974. https:\/\/doi.org\/10.1089\/thy.2006.16.967 (2006).","journal-title":"Thyroid"},{"key":"93275_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-2249.2006.03110.x","volume":"145","author":"B Gopinath","year":"2006","unstructured":"Gopinath, B. et al. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves\u2019 disease. Clin. Exp. Immunol. 145, 56\u201362. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03110.x (2006).","journal-title":"Clin. Exp. Immunol."},{"key":"93275_CR19","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s12276-020-00535-1","volume":"52","author":"JS Woo","year":"2020","unstructured":"Woo, J. S., Jeong, S. Y., Park, J. H., Choi, J. H. & Lee, E. H. Calsequestrin: A well-known but curious protein in skeletal muscle. Exp. Mol. Med. 52, 1908\u20131925. https:\/\/doi.org\/10.1038\/s12276-020-00535-1 (2020).","journal-title":"Exp. Mol. Med."},{"key":"93275_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/opth.s6534","volume":"4","author":"H Lahooti","year":"2010","unstructured":"Lahooti, H., Parmar, K. R. & Wall, J. R. Pathogenesis of thyroid-associated ophthalmopathy: Does autoimmunity against calsequestrin and collagen XIII play a role?. Clin. Ophthalmol. 4, 417\u2013425. https:\/\/doi.org\/10.2147\/opth.s6534 (2010).","journal-title":"Clin. Ophthalmol."},{"key":"93275_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","volume":"16","author":"RS Bahn","year":"1987","unstructured":"Bahn, R. S. & Gorman, C. A. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol. Metab. Clin. N. Am. 16, 391\u2013407. https:\/\/doi.org\/10.1016\/S0889-8529(18)30485-7 (1987).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"93275_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/IOP.0b013e3181e9a063","volume":"27","author":"LR Dagi","year":"2011","unstructured":"Dagi, L. R., Zoumalan, C. I., Konrad, H., Trokel, S. L. & Kazim, M. Correlation between extraocular muscle size and motility restriction in thyroid eye disease. Ophthalm. Plast. Reconstr. Surg. 27, 102\u2013110. https:\/\/doi.org\/10.1097\/IOP.0b013e3181e9a063 (2011).","journal-title":"Ophthalm. Plast. Reconstr. Surg."},{"key":"93275_CR23","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2214\/ajr.170.4.9530066","volume":"170","author":"A Ozgen","year":"1998","unstructured":"Ozgen, A. & Ariyurek, M. Normative measurements of orbital structures using CT. Am. J. Roentgenol. 170, 1093\u20131096. https:\/\/doi.org\/10.2214\/ajr.170.4.9530066 (1998).","journal-title":"Am. J. Roentgenol."},{"key":"93275_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3341\/kjo.2013.27.6.397","volume":"27","author":"KI Woo","year":"2013","unstructured":"Woo, K. I., Kim, Y. D. & Lee, S. Y. Prevalence and risk factors for thyroid eye disease among Korean dysthyroid patients. Korean J. Ophthalmol. 27, 397\u2013404. https:\/\/doi.org\/10.3341\/kjo.2013.27.6.397 (2013).","journal-title":"Korean J. Ophthalmol."},{"key":"93275_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ophtha.2010.04.004","volume":"118","author":"NI Regensburg","year":"2011","unstructured":"Regensburg, N. I., Wiersinga, W. M., Berendschot, T. T., Potgieser, P. & Mourits, M. P. Do subtypes of graves\u2019 orbitopathy exist?. Ophthalmology 118, 191\u2013196. https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.004 (2011).","journal-title":"Ophthalmology"},{"key":"93275_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.22088\/cjim.9.2.178","volume":"9","author":"S Gharib","year":"2018","unstructured":"Gharib, S., Moazezi, Z. & Bayani, M. A. Prevalence and severity of ocular involvement in Graves\u2019 disease according to sex and age: A clinical study from Babol, Iran. Caspian J. Intern Med. 9, 178\u2013183. https:\/\/doi.org\/10.22088\/cjim.9.2.178 (2018).","journal-title":"Caspian J. Intern Med."},{"key":"93275_CR27","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1507\/endocrj.EJ16-0165","volume":"63","author":"JW Kim","year":"2016","unstructured":"Kim, J. W., Woo, Y. J. & Yoon, J. S. Is modified clinical activity score an accurate indicator of diplopia progression in Graves\u2019 orbitopathy patients?. Endocr. J. 63, 1133\u20131140. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0165 (2016).","journal-title":"Endocr. J."},{"key":"93275_CR28","doi-asserted-by":"publisher","first-page":"e0176064","DOI":"10.1371\/journal.pone.0176064","volume":"12","author":"Q Li","year":"2017","unstructured":"Li, Q. et al. Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases. PLoS\u00a0One 12, e0176064\u2013e0176064. https:\/\/doi.org\/10.1371\/journal.pone.0176064 (2017).","journal-title":"PLoS\u00a0One"},{"key":"93275_CR29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/sj.eye.6702603","volume":"21","author":"J Thornton","year":"2007","unstructured":"Thornton, J., Kelly, S. P., Harrison, R. A. & Edwards, R. Cigarette smoking and thyroid eye disease: A systematic review. Eye (Lond.) 21, 1135\u20131145. https:\/\/doi.org\/10.1038\/sj.eye.6702603 (2007).","journal-title":"Eye (Lond.)"},{"key":"93275_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.87.6.773","volume":"87","author":"A Eckstein","year":"2003","unstructured":"Eckstein, A. et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br. J. Ophthalmol. 87, 773. https:\/\/doi.org\/10.1136\/bjo.87.6.773 (2003).","journal-title":"Br. J. Ophthalmol."},{"key":"93275_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","volume":"45","author":"J Pfeilschifter","year":"1996","unstructured":"Pfeilschifter, J. & Ziegler, R. Smoking and endocrine ophthalmopathy: Impact of smoking severity and current vs lifetime cigarette consumption. Clin. Endocrinol. 45, 477\u2013481. https:\/\/doi.org\/10.1046\/j.1365-2265.1996.8220832.x (1996).","journal-title":"Clin. Endocrinol."},{"key":"93275_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4183\/aeb.2009.191","volume":"5","author":"I Cozma","year":"2009","unstructured":"Cozma, I. et al. Variation in thyroid status in patients with Graves\u2019 orbitopathy. Choroid Plexus Pineal Gland Correlat. Med. Anthropol. Comput. Tomography Stud. Intracranial Physiol. Calcif. 5, 191\u2013198. https:\/\/doi.org\/10.4183\/aeb.2009.191 (2009).","journal-title":"Choroid Plexus Pineal Gland Correlat. Med. Anthropol. Comput. Tomography Stud. Intracranial Physiol. Calcif."},{"key":"93275_CR33","first-page":"477","volume":"92","author":"GB Bartley","year":"1994","unstructured":"Bartley, G. B. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans. Am. Ophthalmol. Soc. 92, 477\u2013588 (1994).","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"93275_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","volume":"121","author":"GB Bartley","year":"1996","unstructured":"Bartley, G. B. et al. Clinical features of graves\u2019 ophthalmopathy in an incidence cohort. Am. J. Ophthalmol. 121, 284\u2013290. https:\/\/doi.org\/10.1016\/S0002-9394(14)70276-4 (1996).","journal-title":"Am. J. Ophthalmol."},{"key":"93275_CR35","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/eye.2012.132","volume":"26","author":"SY Jang","year":"2012","unstructured":"Jang, S. Y., Lee, S. Y., Lee, E. J. & Yoon, J. S. Clinical features of thyroid-associated ophthalmopathy in clinically Euthyroid Korean patients. Eye (Lond.) 26, 1263\u20131269. https:\/\/doi.org\/10.1038\/eye.2012.132 (2012).","journal-title":"Eye (Lond.)"},{"key":"93275_CR36","doi-asserted-by":"publisher","first-page":"e0148167","DOI":"10.1371\/journal.pone.0148167","volume":"11","author":"J-Y Lee","year":"2016","unstructured":"Lee, J.-Y., Bae, K., Park, K.-A., Lyu, I. J. & Oh, S. Y. Correlation between extraocular muscle size measured by computed tomography and the vertical angle of deviation in thyroid eye disease. PLoS\u00a0One 11, e0148167. https:\/\/doi.org\/10.1371\/journal.pone.0148167 (2016).","journal-title":"PLoS\u00a0One"},{"key":"93275_CR37","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1210\/jc.2009-2470","volume":"95","author":"SD Lytton","year":"2010","unstructured":"Lytton, S. D. et al. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 95, 2123\u20132131. https:\/\/doi.org\/10.1210\/jc.2009-2470 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"93275_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.iop.0000192649.23508.f7","volume":"22","author":"LR Dragan","year":"2006","unstructured":"Dragan, L. R., Seiff, S. R. & Lee, D. C. Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy. Ophthalm. Plast. Reconstr. Surg. 22, 13\u201319. https:\/\/doi.org\/10.1097\/01.iop.0000192649.23508.f7 (2006).","journal-title":"Ophthalm. Plast. Reconstr. Surg."},{"key":"93275_CR39","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/j.ophtha.2011.03.030","volume":"118","author":"KA Ponto","year":"2011","unstructured":"Ponto, K. A. et al. Clinical relevance of thyroid-stimulating immunoglobulins in graves\u2019 ophthalmopathy. Ophthalmology 118, 2279\u20132285. https:\/\/doi.org\/10.1016\/j.ophtha.2011.03.030 (2011).","journal-title":"Ophthalmology"},{"key":"93275_CR40","doi-asserted-by":"publisher","first-page":"160008","DOI":"10.1530\/EDM-16-0008","volume":"2016","author":"A Tabasum","year":"2016","unstructured":"Tabasum, A., Khan, I., Taylor, P., Das, G. & Okosieme, O. E. Thyroid antibody-negative euthyroid Graves\u2019 ophthalmopathy. Endocrinol. Diabetes Metab. Case Rep. 2016, 160008\u2013160008. https:\/\/doi.org\/10.1530\/EDM-16-0008 (2016).","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"93275_CR41","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2147\/OPTH.S30704","volume":"6","author":"T McCorquodale","year":"2012","unstructured":"McCorquodale, T., Lahooti, H., Gopinath, B. & Wall, J. R. Long-term follow-up of seven patients with ophthalmopathy not associated with thyroid autoimmunity: Heterogeneity of autoimmune ophthalmopathy. Clin. Ophthalmol. 6, 1063\u20131071. https:\/\/doi.org\/10.2147\/OPTH.S30704 (2012).","journal-title":"Clin. Ophthalmol."},{"key":"93275_CR42","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1515\/jpem.2008.21.11.1085","volume":"21","author":"SN Rahhal","year":"2008","unstructured":"Rahhal, S. N. & Eugster, E. A. Thyroid stimulating immunoglobulin is often negative in children with Graves\u2019 disease. J. Pediatr. Endocrinol. Metab. 21, 1085\u20131088. https:\/\/doi.org\/10.1515\/jpem.2008.21.11.1085 (2008).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"93275_CR43","doi-asserted-by":"publisher","first-page":"C335","DOI":"10.1152\/ajpcell.2000.279.2.C335","volume":"279","author":"A Bell","year":"2000","unstructured":"Bell, A. et al. Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. Am. J. Physiol. Cell Physiol. 279, C335-340. https:\/\/doi.org\/10.1152\/ajpcell.2000.279.2.C335 (2000).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"93275_CR44","doi-asserted-by":"publisher","first-page":"12062","DOI":"10.1073\/pnas.211257298","volume":"98","author":"JD Porter","year":"2001","unstructured":"Porter, J. D. et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc. Natl. Acad. Sci. 98, 12062. https:\/\/doi.org\/10.1073\/pnas.211257298 (2001).","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93275-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93275-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93275-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:01:21Z","timestamp":1670065281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93275-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93275"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93275-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"26 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13781"}}